No abstract

Background: A number of papers describe different stem cell lines as the presenting feature to treat diabetes. Case Report: We report a 21 year old female with type 1 diabetes mellitus who was treated with islet like cell aggregates (ICAs) translated from autologous adipose derived mesenchymal stem cells (ADMSCs). Half of the total count of autologous adipose-derived stromal vascular fraction (AD-SVF) was injected intramuscularly. The other half was purified to ADMSCs and translated to ICAs and injected by intra-hepatic route. The patient showed remarkable decrease in her insulin requirement. No side effects were noted related to the treatment. Conclusion: The case study suggests AD-SVF and ADMSCs translated to ICAs is effective alternative strategy for the treatment of juvenile diabetes.

Background: Conventional treatments of osteoarthritis demonstrate only modest clinical benefits without lesion reversal. Autologous mesenchymal stem cells (MSCs) are known to have potential for articular cartilage regeneration. We assess the feasibility and safety of treating osteoarthritis autologous MSCs in combination with platelet rich plasma (PRP). Material & Methods:Patients with chronic knee pain unresponsive to conservative treatments and showing radiological evidence of osteoarthritis were enrolled and injected adipose derived mesenchymal stem cells intra-articularly. The MSC-treated patients displayed significant improvement with Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) score. No adverse events related local or systemic were found. Conclusion: Autologous MSC therapy may be a valid alternative for the treatment of chronic knee osteoarthritis.